Through confirmatory research we desire to reveal the valuable part ACE inhibitors may play in advancing current treatment plans for multiple cancers. Experts believe the potential advantage of ACE Inhibitors against malignancy may be because of the suppression of tumor angiogenesis by blocking a rise protein known as VEGF , which is thought to play a significant part in the reproduction and development of tumors.. Blood pressure drugs connected with reduced threat of cancers Thousands of people currently taking angiotension converting enzyme inhibitors, a kind of medication commonly used to lessen blood pressure, may be doing a lot more than treating their hypertension. Relating to research shown at Digestive Disease Week. 2006 , ACE inhibitors not merely lower blood circulation pressure effectively, however they are also connected with a significant reduction in threat of developing three types of cancers: esophageal, pancreatic and colon.Kaiser Family Foundation. Kaiser Health Information, an editorially independent information service, is an application of the Kaiser Family members Foundation, a nonpartisan healthcare policy research firm unaffiliated with Kaiser Permanente.. Celera seeks FDA premarketing approval for KIF6 Genotyping Assay Celera Company today announced that it has submitted a Premarket Acceptance Application to the U.S. Food and Medication Administration for its KIF6 Genotyping Assay, a new molecular In Vitro diagnostic test designed to detect a marker for threat of cardiovascular system disease independent of traditional risk factors and aid medical evaluation when statin treatment has been considered. ‘This check has been designed to contribute to the prediction of risk for cardiovascular system disease and response to statin therapy.